Sangamo Therapeutics (SGMO) Getting Somewhat Positive Media Coverage, Analysis Finds
News headlines about Sangamo Therapeutics (NASDAQ:SGMO) have trended somewhat positive this week, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Sangamo Therapeutics earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.6125523742589 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media headlines that may have effected Accern’s analysis:
- Brokerages Expect Sangamo Therapeutics Inc (SGMO) Will Post Quarterly Sales of $31.13 Million (americanbankingnews.com)
- -$0.15 Earnings Per Share Expected for Sangamo Therapeutics Inc (SGMO) This Quarter (americanbankingnews.com)
- Sangamo Therapeutics Inc (SGMO) Receives Average Recommendation of “Buy” from Brokerages (americanbankingnews.com)
- Sangamo Therapeutics (SGMO) Appoints Karen Smith to its Board of Directors (streetinsider.com)
- Sangamo Therapeutics Appoints Karen Smith to its Board of Directors (finance.yahoo.com)
A number of analysts recently commented on the stock. Wedbush reiterated a “hold” rating and issued a $8.00 target price on shares of Sangamo Therapeutics in a report on Tuesday, March 13th. BidaskClub downgraded shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 17th. ValuEngine upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Bank of America assumed coverage on shares of Sangamo Therapeutics in a report on Wednesday, June 20th. They issued a “buy” rating and a $24.00 target price on the stock. Finally, Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a report on Tuesday, May 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $22.00.
Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.52). The firm had revenue of $12.60 million during the quarter, compared to analysts’ expectations of $53.09 million. Sangamo Therapeutics had a negative return on equity of 30.96% and a negative net margin of 126.96%. The business’s revenue was up 270.6% on a year-over-year basis. During the same period last year, the business earned ($0.23) earnings per share. analysts expect that Sangamo Therapeutics will post -0.65 EPS for the current fiscal year.
In other news, VP Curt A. Herberts III sold 8,163 shares of Sangamo Therapeutics stock in a transaction that occurred on Friday, April 13th. The shares were sold at an average price of $20.00, for a total value of $163,260.00. Following the transaction, the vice president now directly owns 22,788 shares of the company’s stock, valued at $455,760. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock in a transaction that occurred on Monday, April 16th. The stock was sold at an average price of $19.83, for a total transaction of $99,150.00. Following the completion of the transaction, the chief financial officer now directly owns 12,250 shares in the company, valued at $242,917.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 38,163 shares of company stock worth $669,860. 1.20% of the stock is currently owned by insiders.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.